Serum Interleukin 10 and Interleukin 17 Levels During 6 Months of Oral Antituberculosis Treatment in Pulmonary Tuberculosis and Correlation with Successful Treatment

· Biomolecular, Lung Infection

Fitri Emizola¹, Yani Jane Sugiri¹, Teguh Rahayu Sartono¹, Harun Al Rasyid²
¹Departemen Pulmonologi dan Ilmu Kedokteran Respirasi Fakultas Kedokteran Universitas Brawijaya
²Departemen Ilmu Kesehatan Masyarakat Fakultas Kedokteran Universitas Brawijaya

Background: This study aimed to evaluate the change of IL-10 and IL-17 plasma levels in smear positive pulmonary tuberculosis patients during oral antituberculosis treatment.
Methods: Prospective observational cohort study, IL-10 and IL-17 levels were examined using enzyme-linked immunosorbant assay (ELISA) in 22 new cases of smear AFB positive pulmonary tuberculosis patients in three times: before oral antituberculosis treatment, 2 months, and 6 months after treatment in Saiful Anwar hospital, Malang between January-December 2013.
Results: Mean level of IL-10 before treatment was 123.2 + 79.9 pg/ml, decreased at the 2nd month (114.082 + 65.68 pg/ml), and increased at the 6th month (185.09 + 158.9 pg/ml) but statistically not significant (r=0.25, p-value=0.212). Mean level of IL-17 was high before treatment (255 + 69 pg/ml), decreased at the 2nd month (200 + 69.68 pg/ml), and still decreased until the end of treatment (122 + 124.38 pg/ml); and statistically significant (r= –0.517 p<0.001). The decline of serum IL-17 level correlate with improvement of clinical characteristics, chest x-ray, and sputum conversion during 6 months treatment.
Conclusion: IL-10 level tend to increased during oral antituberculosis treatment, but not significant. IL-17 level were significantly declined during oral antituberculosis treatment and can be considered to use for monitoring of successful treatment. (J Respir Indo. 2015; 35: 12-8)
Keywords: IL-10, IL-17, lung tuberculosis, succesful treatment.

Click here for full paper (PDF)